Biofire Defense LLC

Biofire Defense LLC, a Salt Lake City-based manufacturer of molecular diagnostic systems and reagents, operates as a prime contractor delivering diagnostic platforms, test panels, and related consumables to federal agencies on full-and-open competition with no set-aside posture. The company competes across firm-fixed-price purchase orders, delivery orders, and indefinite delivery vehicles spanning defense, civilian health, and diplomatic agencies.

Biofire Defense's customer base concentrates heavily on defense logistics and biodefense priorities. The top five customers by award count account for 85% of recent activity, led by Defense Logistics Agency Troop Support Medical (4,403 awards, $10.3 million combined potential value) and the Department of the Army Joint Program Executive Office for Chemical and Biological Defense (219 awards, $392.5 million combined potential value). However, the dollar concentration is sharply different: Joint PEO Chemical and Biological Defense anchors 66% of the combined potential value across the top-five-customer ranking, with $392.5 million, while Defense Logistics Agency's high-volume small orders represent only $10.3 million. The Department of State Bureau of Medical Services ranks third by dollars ($36 million across 25 awards) despite lower order count, and the Defense Health Agency ($35.8 million across 35 awards) and Department of Navy Bureau of Medicine and Surgery ($17.9 million across 173 awards) round out the dollar-concentrated set. This split between order volume and dollar value signals that Biofire Defense supplies consumable test kits through high-frequency small orders to DLA while anchoring strategic capability work through larger delivery orders under standing IDIQs with defense customers.

Biofire Defense holds three major parent vehicles anchoring federal procurement access. An Indefinite Delivery Contract (SPE2D015D0008) carries 3,307 task orders worth $3.2 million combined potential value, and a second IDC (SPM2D010D0003) supports 853 task orders for $2.4 million—both likely used by DLA for routine consumable distribution across military medical facilities. The most strategically significant vehicle is IDC W911QY13D0080 with the Army Acquisition Support Center Joint PEO Chemical and Biological Defense, which has generated 178 task orders valued at $127.3 million, positioning this vehicle as the primary contracting mechanism for Biofire Defense's advanced diagnostic system work including the Next Generation Diagnostic System sustainment and product development. Biofire Defense also maintains a Multiple Award Schedule (MAS) position generating 107 task orders worth $6.2 million and a GSA Federal Supply Schedule (GS24F0015N) carrying 71 task orders for $786 thousand. A recent single-award Indefinite Delivery Contract with the Defense Health Agency (awarded October 1, 2025, through September 30, 2030) carries a $4.85 million ceiling for equipment lease and reagent supply to Madigan Army Medical Center, and a $4.5 million single-award Blanket Purchase Agreement with the Department of State Bureau of Administration (March 2025 through March 2027) procures FilmArray test panels and related diagnostics for embassy medical operations worldwide, with 35 call orders issued through December 2025.

Biofire Defense's capability footprint is grounded in molecular diagnostic hardware and consumables for pathogen detection. Named recent work includes a $825 thousand delivery order from Joint PEO Chemical and Biological Defense (June 2026) for cybersecurity image upgrades to the Next Generation Diagnostic System; a $4.65 million purchase order from the Defense Health Agency (April 2026) for a molecular assay analyzer with cost-per-test pricing including reagents, maintenance, and consumables through April 2031; a $2.26 million purchase order from Defense Health Agency (April 2026) for an automated multiplex PCR system to detect DNA/RNA pathogens; a $1.54 million purchase order from Defense Health Agency (April 2025) for a molecular assay analyzer at Camp Pendleton North; and $312 thousand in respiratory panel delivery under the MAS from Bureau of Medicine and Surgery (August 2025). The company's product portfolio centers on the FilmArray and RAZOR Mk II diagnostic systems, Global Fever Special Pathogens Panels, Warrior Panels, Respiratory Panels 2.1, Gastrointestinal Panels, and Sentinel Panels, along with system maintenance, warranty, and reagent supply services. Work performed worldwide spans military medical treatment facilities (Madigan Army Medical Center in Lewis-McChord, Washington; Naval Medical Center San Diego; Guam; Peru), U.S. embassies (Iraq, Kenya, Nigeria, and others), and domestic NIH and civilian state department locations.

Activity has remained relatively flat year over year across the past five years (111 awards in 2022 through 81 in 2025, with 25 in 2026 YTD), though year-to-year variability reflects the dollar concentration: most activity volume flows through high-frequency small consumable orders while strategic capability work under Joint PEO Chemical and Biological Defense generates the largest individual awards. Twelve awards with ultimate completion dates in the next twenty-four months carry combined potential value of $25.3 million and face recompete risk, including the Madigan Army Medical Center equipment lease IDC (completion September 2026) and multiple delivery orders under Joint PEO Chemical and Biological Defense.

Across SCI-reportable federal service contracts, Biofire Defense invoiced $14.9 million from FY2022 through FY2025, with $7.8 million in FY2025 and $6.9 million in FY2024, supporting roughly 14.5 FTEs in FY2025 and 12.9 FTEs in FY2024. On federal services contracts captured in SCI, median government-paid rates ran around $81.67 per hour, with senior labor pricing reaching $236.90 per hour and entry-level rates near $20.08 per hour. SCI shows minimal subcontractor engagement (6% of total contractor hours across prime records) with only one named subcontractor reported. Biofire Defense operates primarily as a self-delivery prime, building its own teams rather than outsourcing core diagnostic development and manufacturing.

As a prime contractor, Biofire Defense also subcontracts to larger defense integrators: the company delivered diagnostic panels and related NGDS components under Prism Maritime, Inc. prime contracts for Chemical, Biological, Radiological, and Nuclear Defense support services (awards August 2024, September 2024, November 2024, April 2025, January 2026), medical support services to Iraq under KBR Services, LLC (January 2026), and lab instrument manufacturing work under KBR Wyle Services, LLC (July 2026). These subcontracts reflect Biofire Defense's role as a specialized diagnostic component supplier embedded within larger defense support contract hierarchies, particularly for overseas and theater-deployed medical operations.

Idaho Technology manufacturers analytical laboratory instruments and develops, and sells the fastest high-speed air thermal, the R.A.P.I.D. System, RapidCycler and HR-1.